ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer-Reference-Cited by-同舟云学术

ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer

Published:2022-09-13 Issue:11 Volume:54 Page:1671-1683
ISSN:1672-9145
Container-title:Acta Biochimica et Biophysica Sinica
language:en
Short-container-title:ABBS

Author:

Hong Hi-Ju,Shao Yanfei,Zhang Sen,Yang Guang,Jia Hongtao,Yang Xiao,Huang Ling,Li Shuchun,Aikemu Batuer,Zhang Luyang,Ma Junjun,Zang Lu,Sun Jing,Zheng Minhua

Publisher

China Science Publishing & Media Ltd.

Subject

General Medicine,Biochemistry,Biophysics

Link

https://engine.scichina.com/doi/pdf/3D4DC20F4D4A4422AFBD13F6A46471E5

Reference40 articles.

1. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391: 1023-1075.

2. Kohne C, Bokemeyer C, Heeger S, Sartorius U, Rougier P, Van Cutsem E. Efficacy of chemotherapy plus cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer (mCRC): analysis of CRYSTAL and OPUS studies. J Clin Oncol, 2011, 29:

3. Cheng AL, Cornelio G, Shen L, Price T, Yang TS, Chung IJ, Dai GH. Efficacy, tolerability, and biomarker analyses of once-every-2-weeks cetuximab plus first-line FOLFOX or FOLFIRI in patients with KRAS or all RAS wild-type metastatic colorectal cancer: the phase 2 APEC study. Clin Colorectal Cancer, 2017, 16: e73-e88.

4. Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol, 2013, 31: 1931-1938.

5. Modest DP, Martens UM, Riera-Knorrenschild J, Greeve J, Florschütz A, Wessendorf S, Ettrich T. FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, phase II VOLFI study (AIO KRK0109). J Clin Oncol, 2019, 37: 3401-3411.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined transcriptomics and metabolomics to reveal the effects of copper exposure on the liver of rainbow trout(Oncorhynchus mykiss);Ecotoxicology and Environmental Safety;2024-10

2. Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer;Acta Biochimica et Biophysica Sinica;2023-06-01